ホーム>>Signaling Pathways>> Ubiquitination/ Proteasome>> Proteasome>>FK-448 Free base

FK-448 Free base

カタログ番号GC31563

FK-448 遊離塩基は、キモトリプシンの効果的かつ特異的な阻害剤であり、IC50 は 720 nM です。

Products are for research use only. Not for human use. We do not sell to patients.

FK-448 Free base 化学構造

Cas No.: 85858-76-0

サイズ 価格 在庫数
1mg
$414.00
Please Inquire
5mg
$827.00
Please Inquire
10mg
$1,471.00
Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

FK-448 Free base is an effective and specific inhibitor of chymotrypsin, with an IC50 of 720 nM.

FK-448 Free base is an effective and specific inhibitor of chymotrypsin, with an IC50 of 720 nM. FK-448 Free base slightly inhibits esterolysis of Trypsin and Thrombin, with IC50s of 780 and 35 μM, respectively, but shows no effects on esterolysis of plasmin, plasma kallikrein or pancreas kallikrein, with IC50s of all >1 mM[1]. FK-448 moderately inhibits hydrolytic activities of cathepsin G with an IC50 of 15 μM[2].

FK-448 (20 mg/kg, i.p.) results in a decrease in the blood glucose level, and inhibits the degradation of insulin by pancreatic enzymes in rats. FK-448 (20 mg/kg, p.o.) also decreases the blood glucose level, and increases plasma IRI level in dogs[2].

[1]. Fujii S, et al. New synthetic inhibitors of chymotrypsin. J Biochem. 1984 Feb;95(2):319-22. [2]. Fujii S, et al. Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs. J Pharm Pharmacol. 1985 Aug;37(8):545-9.

レビュー

Review for FK-448 Free base

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for FK-448 Free base

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.